Sjogren's Syndrome clinical trials

The registry lists 330 studies for Sjogren's Syndrome across more than 10 countries. 99 are recruiting or about to start. 222 of them are mainly about Sjogren's Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Sjogren's Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 149
Recruiting: 67
Status unknown: 37
Not yet recruiting: 28
Terminated: 19
Active, not recruiting: 13

Phase

Phase 2: 82
Phase 1: 46
Phase 3: 28
Phase 4: 18
Early Phase 1: 13

Where

United States: 111
France: 58
China: 55
Taiwan: 31
United Kingdom: 27
Italy: 26

Who runs them

National Institute of Dental and Craniofacial Research (NIDCR) (17) · Novartis Pharmaceuticals (15) · Taipei Veterans General Hospital, Taiwan (8) · University of Sao Paulo General Hospital (8) · Peking Union Medical College Hospital (8) · Amgen (7) · University Hospital, Brest (6) · Assistance Publique - Hôpitaux de Paris (5)

What is being tested here

Drugs under test in Sjogren's Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
YTS109	3	0	3
Anti-CD19 CAR T Cells Preparation	2	0	2
Ianalumab	1	4	6
Rituximab	1	1	5
Dazodalibep	1	3	4
Belimumab	1	0	4
Deucravacitinib	1	2	2
Tofacitinib	1	0	2
Iguratimod	1	0	2
BRL-301	1	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · JAK inhibitors 2 open · Calcineurin inhibitors 7

Coming up

9phase 3 studies under way

26studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome · Phase 3 · Bristol-Myers Squibb
Feb 2027Nipocalimab in Moderate to Severe Sjogren's Disease · Phase 3 · Janssen Research & Development, LLC
Nov 2026Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases · China Immunotech (Beijing) Biotechnology Co., Ltd.
Nov 2026An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · China Immunotech (Beijing) Biotechnology Co., Ltd.
Dec 2026Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients · Hospital Universitario Araba
Dec 2026A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE · Lubris Bio Pty Ltd
Dec 2026Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases · Nanjing Bioheng Biotech Co., Ltd.
Dec 2026Ultra-High Frequency Ultrasonography in Sjögren's Syndrome · University of Pisa
Dec 2026Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome · Center For Sight
Jan 2027Maternal Autoimmune Disease Research Alliance (MADRA) Registry · Duke University

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger. 9 (13%) take children under 18. 3 (4%) are for women only and 0 (0%) for men only; 11 (16%) take healthy volunteers.

Recruiting studies that take each age, of 67
Age	Women	Men
10	8 (12%)	7 (10%)
18	60 (90%)	58 (87%)
30	64 (96%)	61 (91%)
40	64 (96%)	61 (91%)
50	64 (96%)	61 (91%)
65	64 (96%)	61 (91%)
75	48 (72%)	46 (69%)
85	37 (55%)	35 (52%)

Across all 330 studies, recruiting or not: 40% stop at 75 or younger and 16% at 65; 12% take children; 9% are for women only and 0% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sjogren's Syndrome studies take

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	25 mo17–43 · 26 studies	—	—
Interventional, no phase	18 mo10–35 · 44 studies	—	18 mo10–35 · 39 studies
Observational	64 mo21–… · 40 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 330. Browse all 330 → or search them.